Teva Pharma Belgium has announced new and unique indication and reimbursement criteria for LONQUEX® (lipegfilgrastim) 6 mg, effective from 1 March 2023!
LONQUEX® is now indicated for adults and children aged 2 years and above to reduce neutropenia duration and the incidence of febrile neutropenia in patients undergoing cytotoxic chemotherapy for malignancies (except for chronic myeloid leukemia and myelodysplastic syndromes). With these exceptional reimbursement criteria for LONQUEX®, pediatric patients can benefit from optimal protection against chemotherapy-induced neutropenia with just one injection per chemotherapy cycle.
The reimbursement request of LONQUEX®, regarding the new criteria for adults and children (PFS and vial) are available as usual via the eHealth platform from 1 March 2023.
For more information, please refer to this document or contact BSPHO to connect you with the TEVA Business Unit Manager (Nathalie Plasman).